New York Heart Association class is strongly associated with mortality beyond heart failure in symptomatic women.

Online publish-ahead-of-print 21 December 2020 Cardiovascular disease is the leading cause of mortality in women worldwide. The New York Heart Association’s (NYHA) functional classification was specifically designed to estimate the general condition of heart failure patients and to indicate their mortality risk. Its use is now being extended to include complaints of chest pain, dyspnoea, and fatigue.

New York Heart Association classification is easy to determine, and it is often used at outpatient cardiology clinics to assess risk. However, risk stratification tools for cardiovascular disease are mainly investigated in men. Therefore, cardiologists often find it difficult to estimate risk in the growing population of symptomatic women referred by general practitioners. Since the association between NYHA class and mortality may differ between sexes and patient domains,, we studied this association in more than 9000 individuals visiting one of 13 outpatient cardiology clinics during 2007 and 2018.

We extracted data from the electronic health records of individuals visiting a clinic for the first time with complaints of chest pain, dyspnoea, or fatigue, with a documented NYHA class. Mortality was assessed by linking our data to the national database, Statistics Netherlands. We estimated survival functions using the Kaplan–Meier curves and Cox proportional hazards regression analysis (adjusted for age and SCORE). The UMCU Medical Research Ethical Committee judged that the Dutch Medical Research Involving Human Subjects Act does not apply to the data collection used for this study.

Of 9011 selected individuals, 4782 (53%) were female of whom 1450 were referred for dyspnoea, 2801 for chest pain, and 531 for fatigue. New York Heart Association Classes I, II, and III–IV (out of IV) were documented in these women: 2196 (46%), 2077 (43%), and 509 (11%), respectively; in the 4229 men, this distribution was 2114 (50%), 1688 (40%), and 428 (10%), respectively (Figure ). After a median of 8 years’ follow-up, 354 (7%) women and 415 (10%) men had died.

New York Heart Association class in symptomatic women at the outpatient cardiology clinic. (A) Prevalence of complaints in women. (B) Baseline table of symptomatic women. (C) Mortality during follow-up according to New York Heart Association class. (D) Hazard ratio for all-cause mortality in all men, all women and stratified by complaint in women. BMI, body mass index; NYHA, New York Heart Association Classification; SCORE, Systematic COronary Risk Evaluation; SD, standard deviation.

Survival analysis showed that a higher NYHA class was associated with mortality in all women (Figure ). Multivariate Cox regression analysis confirmed that mortality risk increased with higher NYHA class in women (NYHA Class II vs. I hazard ratio (HR) 1.7, 95% confidence interval (CI) 1.3–2.3; NYHA Class III–IV vs. I HR 3.9, 95% CI 2.8–5.5). This association became stronger after adjustment for SCORE (NYHA Class II vs. I HR 3.3, 95% CI 2.2–4.9, NYHA Class III–IV vs. I HR 7.8, 95% CI 4.9–12.2). Results were similar in men (NYHA Class II vs. I HR 3.3, 95% CI 2.3–4.6, NYHA Class III–IV vs. I HR 7.1, 95% CI 4.8–10.5). Furthermore, NYHA class was associated with a higher mortality risk in all complaint groups in women in NYHA class II (chest pain HR 1.4, 95% CI 0.8–2.2, dyspnoea HR 1.2, 95% CI 0.7–2.1, fatigue HR 0.9, 95% CI 0.4–2.1) and NYHA Class III–IV (chest pain: HR 2.4, 95% CI 1.3–4.6, dyspnoea HR 2.6, 95% CI 1.5–4.6, fatigue HR 2.5, 95% CI 1.0–6.0).

Thus, functional grading of complaints with NYHA classification provides important information on mortality risk in women presenting with a variety of cardiac complaints, beyond diagnosed heart failure. It indicates higher mortality risk in women suffering from NYHA Class III–IV complaints who may therefore warrant close attention.

Data Availability

The data underlying this article will be shared on reasonable request to the corresponding author.

Conflict of interest: none declared.

Funding

The DCVA (2020B004—IMPRESS), an ERC consolidator grant (866478—UCARE), and the Dutch Heart Foundation (2018B017—CVON-AI).